A Prospective Study on Comparing the efficacy of Combination Therapy and Monotherapy of DMARDs in Patients with Rheumatoid Arthritis

There is growing evidence from randomized clinical trials and longitudinal observational studies that conservative single drug therapy with disease-modifying anti-rheumatic drugs (DMARDs) can alter the clinical course of rheumatoid arthritis, however in most patients the assistances are inadequate[3-7]. [...]additional authoritative therapies are desirable, such as the usage of more than one DMARD concurrently in the hope of additive efficacy[8,9]. The improved practice of combinations has progressed for three main reasons: initially, rheumatologists have been gradually disinclined to agree incomplete improvement of their patients when remission seems possible; then, the recognition that most DMARDs lose whatever efficacy they do have over time; and finally, the latest accumulation of data that combinations can be given safely and with better efficacy than mono-therapy [10-13] Consequently, in the current study, we compared the efficacy of a DMARD combination including methotrexate, Sulphasalazine, hydrochloroquine and low-dose prednisolone with the same DMARDs as single treatment in patients with active rheumatoid arthritis. [...]line drug therapy for rheumatoid arthritis.